Horm Metab Res 1982; 14(2): 98-100
DOI: 10.1055/s-2007-1018934
© Georg Thieme Verlag, Stuttgart · New York

Plasma 25-Hydroxycholecalciferol in Oral Sulfonylurea Treated Diabetes Mellitus

J. Štěpán1 , H. Wilczek1 , V. Justová1 , T. Havránek3 , F. Škrha2 , Z. Wildtová1 , J. Formánková1 , V. Pacovský1
  • 13rd Department of Internal Medicine, Charles University Faculty of Medicine, Prague, Czechoslovakia
  • 2Policlinic Department of Internal Medicine, Charles University Faculty of Medicine, Prague, Czechoslovakia
  • 3Centre of Biomathematics, Czechoslovak Academy of Sciences, Prague, Czechoslovakia
Further Information

Publication History

1980

1981

Publication Date:
14 March 2008 (online)

Summary

In oral sulfonylurea treated diabetics, decreased plasma 25-hydroxycholecalciferol and increased activity of bone isoenzyme of serum alkaline phosphatase and urinary hydroxyproline excretion was found when compared with control subjects. In stepwise regression analysis significant relationships were found between bone isoenzyme, urinary hydroxyproline excretion, serum calcium levels and blood glucose levels. The partial correlation and multivariate regression analysis, showed that in oral sulfonylurea treated patients, but not in insulin treated patients, the activity of bone isoenzyme of serum alkaline phosphatase was significantly inverse dependent on the 25-hydroxycholecalciferol levels in plasma. Oral sulfonylurea agents which are known to induce the hepatic microsomal system seem to be an additional factor to poor control of diabetes, leading to osteopathy.